A detailed history of Vicus Capital transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Vicus Capital holds 4,375 shares of GILD stock, worth $394,581. This represents 0.03% of its overall portfolio holdings.

Number of Shares
4,375
Previous 5,806 24.65%
Holding current value
$394,581
Previous $398,000 8.04%
% of portfolio
0.03%
Previous 0.04%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

SELL
$66.59 - $83.99 $95,290 - $120,189
-1,431 Reduced 24.65%
4,375 $366,000
Q2 2024

Jul 23, 2024

SELL
$63.15 - $72.88 $31,890 - $36,804
-505 Reduced 8.0%
5,806 $398,000
Q1 2024

Apr 17, 2024

BUY
$71.58 - $87.29 $106,654 - $130,062
1,490 Added 30.91%
6,311 $462,000
Q4 2023

Feb 01, 2024

SELL
$73.27 - $83.09 $73,782 - $83,671
-1,007 Reduced 17.28%
4,821 $390,000
Q3 2023

Oct 23, 2023

BUY
$73.94 - $80.67 $53,236 - $58,082
720 Added 14.1%
5,828 $436,000
Q2 2023

Aug 17, 2023

BUY
$76.01 - $86.7 $106,109 - $121,033
1,396 Added 37.61%
5,108 $393,000
Q1 2023

May 02, 2023

SELL
$77.31 - $88.08 $22,033 - $25,102
-285 Reduced 7.13%
3,712 $307,000
Q4 2022

Feb 15, 2023

SELL
$62.32 - $89.47 $11,965 - $17,178
-192 Reduced 4.58%
3,997 $343,000
Q3 2022

Nov 08, 2022

BUY
$59.54 - $68.01 $28,579 - $32,644
480 Added 12.94%
4,189 $258,000
Q2 2022

Aug 10, 2022

BUY
$57.72 - $65.01 $13,333 - $15,017
231 Added 6.64%
3,709 $229,000
Q1 2022

May 11, 2022

BUY
$57.92 - $72.58 $15,522 - $19,451
268 Added 8.35%
3,478 $207,000
Q4 2021

Feb 10, 2022

BUY
$64.88 - $73.64 $208,264 - $236,384
3,210 New
3,210 $210,000
Q3 2021

Oct 14, 2021

SELL
$67.69 - $73.03 $220,127 - $237,493
-3,252 Closed
0 $0
Q2 2021

Aug 10, 2021

SELL
$63.47 - $69.35 $21,452 - $23,440
-338 Reduced 9.42%
3,252 $224,000
Q1 2021

May 04, 2021

BUY
$60.0 - $68.46 $215,400 - $245,771
3,590 New
3,590 $232,000
Q4 2020

Feb 01, 2021

SELL
$56.65 - $64.55 $272,996 - $311,066
-4,819 Closed
0 $0
Q3 2020

Nov 12, 2020

SELL
$62.1 - $78.08 $115,381 - $145,072
-1,858 Reduced 27.83%
4,819 $305,000
Q2 2020

Aug 03, 2020

BUY
$72.34 - $84.0 $72,557 - $84,252
1,003 Added 17.68%
6,677 $514,000
Q1 2020

May 07, 2020

SELL
$62.63 - $80.22 $54,863 - $70,272
-876 Reduced 13.37%
5,674 $424,000
Q4 2019

Feb 04, 2020

SELL
$61.62 - $67.78 $35,000 - $38,499
-568 Reduced 7.98%
6,550 $426,000
Q3 2019

Nov 18, 2019

SELL
$62.51 - $69.0 $45,819 - $50,577
-733 Reduced 9.34%
7,118 $451,000
Q2 2019

Aug 08, 2019

SELL
$61.87 - $69.38 $22,830 - $25,601
-369 Reduced 4.49%
7,851 $530,000
Q1 2019

May 02, 2019

BUY
$62.53 - $70.05 $21,948 - $24,587
351 Added 4.46%
8,220 $534,000
Q4 2018

Feb 07, 2019

SELL
$60.54 - $79.0 $4,056 - $5,293
-67 Reduced 0.84%
7,869 $492,000
Q3 2018

Nov 13, 2018

SELL
$71.28 - $78.92 $4,561 - $5,050
-64 Reduced 0.8%
7,936 $613,000
Q2 2018

Aug 02, 2018

SELL
$64.88 - $75.68 $165,249 - $192,756
-2,547 Reduced 24.15%
8,000 $567,000
Q1 2018

May 07, 2018

SELL
$72.84 - $88.8 $49,167 - $59,940
-675 Reduced 6.01%
10,547 $795,000
Q4 2017

Jan 25, 2018

SELL
$71.15 - $83.52 $19,495 - $22,884
-274 Reduced 2.38%
11,222 $804,000
Q3 2017

Oct 27, 2017

BUY
$72.11 - $85.47 $828,976 - $982,563
11,496
11,496 $931,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Vicus Capital Portfolio

Follow Vicus Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vicus Capital, based on Form 13F filings with the SEC.

News

Stay updated on Vicus Capital with notifications on news.